Vol. 16 No. 3 (2012)
ONCOLOGY

Hypofractionated stereotactic radiotherapy for malignant tumors of the lung

PDF (Русский)
  • O. Anikeeva,
  • Ye. Samoylova,
  • P. Filatov,
  • O. Pashkovskaya
O. Anikeeva
Academician E.N. Meshalkin Novosibirsk Research Institute of Circulation Pathology
Bio
Ye. Samoylova
Academician E.N. Meshalkin Novosibirsk Research Institute of Circulation Pathology
Bio
P. Filatov
Academician E.N. Meshalkin Novosibirsk Research Institute of Circulation Pathology
Bio
O. Pashkovskaya
Academician E.N. Meshalkin Novosibirsk Research Institute of Circulation Pathology
Bio
DOI: https://doi.org/10.21688/1681-3472-2012-3-61-66

Published 2012-09-25

Keywords

  • STEREOTACTIC RADIOTHERAPY,
  • HYPOFRACTIONATED,
  • TOXICITY,
  • DOSE ESCALATION,
  • DOSE TO NORMAL TISSUE

How to Cite

Anikeeva, O., Samoylova, Y., Filatov, P., & Pashkovskaya, O. (2012). Hypofractionated stereotactic radiotherapy for malignant tumors of the lung. Patologiya Krovoobrashcheniya I Kardiokhirurgiya, 16(3), 61–66. https://doi.org/10.21688/1681-3472-2012-3-61-66

Copyright (c) 2012 Anikeeva O.Yu., Samoylova Ye.A., Filatov P.V., Pashkovskaya O.A.

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Abstract

Hypofractionated stereotactic radiotherapy was used for 26 patients at medically inoperable stage I of non-small cell lung cancer with dose escalation of 48-54 Gy prescribed at 90 or 95% isodose level in 3-4 fractions. Nine-months local control and cancer-specific survival were 82.0 and 66.8% respectively, with minimal toxicity. For metastatic lung tumors local control was obtained in 92% cases. Hypofractionated stereotactic radiation therapy (SBRT) is safe and feasible for the treatment of inoperable primary lung cancer and single lung metastasis.
PDF (Русский)

References

  1. Чисов В.И. Онкология: национальное руководство. М., 2008. C. 128-168.
  2. Brown W.T. et al. // Comput. Aided. Surg. 2007. V. 12 (5). P. 253-261.
  3. Charlson M.E., Pompei P., Ales K.L., MacKenzie C.R. // J. Chronic Dis. 1987. V. 40. P. 373-383.
  4. Sawada S., Komori E., Yamashita M. et al. // Surg. Endosc. 2007. V. 21. P. 1607-1611.
  5. Kong F.M., Ten Haken R.K., Schipper M.J. et al. // Int. J. Rad. Oncol. Biol. Phys. 2005. V. 63. P. 324-333.
  6. Jeremic B., Brady L.W. et al. Radiation Oncology. 2011.
  7. Brock J., Ashley S., Bedford J. et al. // Clinical Oncology. 2008. V. 20 (9). P. 666-676.
  8. Bezjak А., Bradley J., Gaspar L. et al. // J. Radiat. Oncol. Biol. Phys. 2011. V. 61. P. 123-1210.
  9. Fenwick J.D., Nahum A.E., Malik Z.I. et al. // Clin. Oncol. 2009 DOI:10.1016/j.clon.2008.12.01
  10. Пасов В.В., Зубова Н.Д., Иволгин Е.М. // Сибирский онкологический журнал. 2009. № 6 (36). С. 58-61.
  11. Giraud P. et al. // Lung. Cancer. 2006. V. 51 (1). Р. 41-51.
  12. Panakis N., McNair H.A., Christian J.A. et al. // Radiother. Oncol. 2008. V. 87. Р. 65-73.
  13. Wulf J., Haedinger U., Oppitz U. et al. // Int. J. Rad. Oncol. Biol. Phys. 2004. V. 60. P. 186-196.
  14. Rodrigues G., Lock M., D'Souza D. et al. // Radiother. Oncol. 2004. V. 71. Р. 127-138.
  15. Кутузова А.Б., Лелюк В.Г., Гуськова А.К. // Медицинская радиология и радиационная безопасность. 2000. Т. 47, № 3. С. 66-79.